BBIO
The bull thesis isn’t budging
BridgeBio Pharma is still getting the rosy treatment: the stock remains a Buy, with the case built around Attruby’s commercial rollout and a pipeline stuffed with late-stage shots on goal in rare genetic diseases. In other words, the story is less “one drug to rule them all” and more “please, several of these programs work.”
Why the market should care
The pitch is pretty simple: BridgeBio’s valuation is being supported by the idea that it could end up with four potential blockbusters by 2030. That’s a lot of future promise baked into one ticker, which is great until you remember biotech timelines have a talent for turning optimism into a long hallway of delays.
The Attruby problem, in plain English
Yes, Attruby is already out in the wild, but it won’t get to coast forever. The article flags coming pressure from:
- Vyndaqel generics
- Vyndamax patent expiry
- Formularies that may get a little less friendly over time
Management’s answer is basically: our drug is better. Investors usually like hearing that. They like seeing sales, data, and market share more.
Big picture
This is still a classic biotech balancing act: near-term commercialization versus long-dated pipeline dreams. If BridgeBio keeps hitting milestones in 2026 and 2027, the current valuation story could look smart. If not, the stock may discover that “bullish” is not a business model.